Polydeoxyribonucleotide attenuates dexamethasone-induced skeletal muscle atrophy by suppressing oxidative stress and regulating muscle protein turnover
Abstract
Glucocorticoid-induced muscle atrophy is characterized by excessive oxidative stress and disrupted muscle protein homeostasis. Polydeoxyribonucleotide (PDRN) exerts tissue-protective and regenerative effects; however, its therapeutic potential in muscle atrophy remains unclear. This study investigated the protective effects of PDRN against dexamethasone (DEX)-induced muscle atrophy in vitro and in vivo. Differentiated C2C12 myotubes were treated with PDRN in the presence or absence of DEX (100 µM). PDRN showed no cytotoxicity, and concentrations of 10, 25, and 50 µg/mL were selected for subsequent experiments. PDRN significantly attenuated DEX-induced myotube thinning and reduced intracellular reactive oxygen species. For in vivo evaluation, C57BL/6 mice received DEX (25 mg/kg/day) for 14 days with or without intramuscular PDRN administration. PDRN treatment improved treadmill performance and preserved GCM mass compared with DEX-treated mice. Histological analyses demonstrated significant increases in muscle fiber area and minimum Feret diameter following PDRN treatment. Furthermore, PDRN reduced oxidative damage, as evidenced by decreased 4-hydroxynonenal staining and malondialdehyde levels while restoring glutathione content. PDRN also upregulated nuclear factor erythroid 2-related factor 2 signaling and normalized antioxidant-related gene expression. In addition, PDRN enhanced expression of anabolic markers, including insulin-like growth factor-1, myogenic differentiation…
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.